Genetically modified T cells successfully migrated to and penetrated a deadly type of brain tumor known as glioblastoma (GBM) in a clinical trial of the new therapy, but the cells triggered an immunosuppressive tumor microenvironment and faced a complex mutational landscape that will need to be overcome to better treat this aggressive cancer, Penn Medicine researchers report in a new study this week in Science Translational Medicine. Co-authors of the study include Department members Drs. MacLean Nasrallah, Jennifer Morrissette, Bruce Levine, and Carl June.
Read the Department of Communications news release
AAAS news